Biological markers in amyotrophic lateral sclerosis: help or hindrance?
Biological markers play an important role in the development of the understanding of a disease, its diagnosis and treatment. This is particularly true of amyotrophic lateral sclerosis (ALS) at this time. We need better biological markers for the diagnosis, for improved understanding of the underlying pathogenetic mechanisms, and for assistance in new drug development. This review of currently available biological and surrogate markers in ALS discusses novel approaches to the use of such markers, and new drugs for the treatment of ALS.
Bradley
W G
WG
Department of Neurology, University of Miami School of Medicine, FL 33101, USA. wbradley@med.miami.edu
D000690:Amyotrophic Lateral Sclerosis / Q000175:diagnosis* / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D015415:Biomarkers; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans
D015415:Biomarkers